Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2004)
Bone Health and Osteoporosis: a report of the Surgeon General
L. Raisz (2005)
Pathogenesis of osteoporosis: concepts, conflicts, and prospects.The Journal of clinical investigation, 115 12
Anjali Sharma, Fang Tian, M. Yin, M. Keller, Mardge Cohen, P. Tien (2012)
Association of Regional Body Composition With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women: Women's Interagency HIV StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 61
J. Womack, J. Goulet, C. Gibert, C. Brandt, C. Chang, B. Gulanski, L. Fraenkel, K. Mattocks, D. Rimland, M. Rodriguez‐Barradas, J. Tate, M. Yin, A. Justice (2011)
Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male VeteransPLoS ONE, 6
(2005)
HAART - induced immune reconstitution : a driving force behind bone resorption in HIV / AIDS . Paper # 78 . 18 th Conference on Retroviruses and Opportunistic Infections , Boston ,
M. Grijsen, S. Vrouenraets, R. Steingrover, P. Lips, P. Reiss, F. Wit, J. Prins (2010)
High prevalence of reduced bone mineral density in primary HIV-1-infected menAIDS, 24
Kojiro Sato, Ayako Suematsu, Kazuo Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, Sakae Tanaka, T. Kodama, S. Akira, Y. Iwakura, D. Cua, H. Takayanagi (2006)
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionThe Journal of Experimental Medicine, 203
A. Bonjoch, M. Figueras, C. Estany, N. Pérez-Álvarez, J. Rosales, L. Río, S. Gregorio, J. Puig, G. Gómez, B. Clotet, E. Negredo (2010)
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort studyAIDS, 24
C. Cazanave, M. Dupon, V. Lavignolle-Aurillac, N. Barthe, S. Lawson-Ayayi, N. Mehsen, P. Mercié, P. Morlat, R. Thiébaut, F. Dabis (2008)
Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 22
T. Vikulina, X. Fan, M. Yamaguchi, S. Roser‐Page, M. Zayzafoon, D. Guidot, I. Ofotokun, M. Weitzmann (2010)
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic ratsProceedings of the National Academy of Sciences, 107
B. Grund, G. Peng, C. Gibert, J. Hoy, R. Isaksson, J. Shlay, E. Martinez, P. Reiss, F. Visnegarwala, A. Carr (2009)
Continuous antiretroviral therapy decreases bone mineral densityAIDS, 23
H. Stellbrink, C. Orkin, J. Arribas, J. Compston, J. Gerstoft, E. Wijngaerden, A. Lazzarin, G. Rizzardini, H. Sprenger, J. Lambert, G. Stūre, D. Leather, S. Hughes, P. Zucchi, Helen Pearce (2010)
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51 8
R. Kalayjian, J. Spritzler, Minya Pu, A. Landay, R. Pollard, V. Stocker, Lena-Al Harthi, B. Gross, I. Francis, S. Fiscus, P. Tebas, R. Bosch, V. Valcour, M. Lederman (2005)
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease.The Journal of infectious diseases, 192 9
P. Aukrust, C. Haug, T. Ueland, E. Lien, F. Müller, T. Espevik, J. Bollerslev, S. Frøland (1999)
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy.The Journal of clinical endocrinology and metabolism, 84 1
R. Güerri-Fernández, P. Vestergaard, C. Carbonell, H. Knobel, F. Avilés, Alberto Castro, X. Nogués, D. Prieto-Alhambra, A. Díez-Pérez (2013)
HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population‐based cohort studyJournal of Bone and Mineral Research, 28
(2012)
Prospective data of greatest duration with respect to BMD endpoints
E. Cotter, A. Malizia, N. Chew, W. Powderly, P. Doran (2007)
HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development.AIDS research and human retroviruses, 23 12
Yan Li, G. Toraldo, Aimin Li, Xiaoying Yang, Hongying Zhang, Wei-Ping Qian, M. Weitzmann (2007)
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.Blood, 109 9
K. Mayer, G. McComsey, P. Tebas, E. Shane, M. Yin, E. Overton, Jeannie Huang, G. Aldrovandi, S. Cardoso, J. Santana, T. Brown (2010)
Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51 8
D. Gibellini, M. Borderi, E. Crignis, Ronny Cicola, F. Vescini, R. Caudarella, F. Chiodo, M. Re (2007)
RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV‐1‐positive menJournal of Medical Virology, 79
K. Mondy, K. Yarasheski, W. Powderly, M. Whyte, Sherry Claxton, Debra DeMarco, M. Hoffmann, P. Tebas (2003)
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 36 4
M. Mary-Krause, J. Viard, Béatrice Ename-Mkoumazok, M. Bentata, M. Valantin, P. Missy, Iuliana Darasteanu, C. Roux, S. Kolta, D. Costagliola, S. Rozenberg (2012)
Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 15 4
D. Gibellini, E. Crignis, C. Ponti, M. Borderi, A. Clo, A. Miserocchi, P. Viale, M. Re (2010)
HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiation.Biochemical and biophysical research communications, 401 3
M. Ryan, R. Shepherd, J. Leavey, Yuhao Gao, F. Grassi, F. Schnell, Wei-Ping Qian, G. Kersh, M. Weitzmann, R. Pacifici (2005)
An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency.Proceedings of the National Academy of Sciences of the United States of America, 102 46
Cross-sectional data from untreated HIV-positive individuals determined greater lean mass as a predictor of greater BMD. Higher CD4 þ T-cell count was associated with higher lean mass
Ricardo Franco, M. Saag (2013)
When to start antiretroviral therapy: as soon as possibleBMC Medicine, 11
A. Moore, A. Vashisht, C. Sabin, A. Mocroft, S. Madge, A. Phillips, J. Studd, Margaret Johnson (2001)
Reduced bone mineral density in HIV-positive individuals.AIDS, 15 13
Utilizing data for RCT, lower CD4 þ T-cell count at initiation was associated with greater reductions in BMD, suggesting ART initiation at higher CD4 þ cell count may attenuate ART-related reductions
J. Lundgren, A. Babiker, F. Gordin, Á. Borges, J. Neaton (2013)
When to start antiretroviral therapy: the need for an evidence base during early HIV infectionBMC Medicine, 11
M. Bolland, T. Wang, A. Grey, G. Gamble, I. Reid (2011)
Stable bone density in HAART-treated individuals with HIV: a meta-analysis.The Journal of clinical endocrinology and metabolism, 96 9
P. Grant, D. Kitch, G. McComsey, M. Dubé, R. Haubrich, Jeannie Huang, S. Riddler, P. Tebas, A. Zolopa, A. Collier, T. Brown (2013)
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57 10
(2012)
on behalf of the AGEhIV Cohort Study Group. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study
A. McDermott, A. Shevitz, T. Knox, R. Roubenoff, J. Kehayias, S. Gorbach (2001)
Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.The American journal of clinical nutrition, 74 5
M. Dubé, D. Qian, Hannah Edmondson-Melançon, F. Sattler, D. Goodwin, Carmen Martinez, V. Williams, Debra Johnson, T. Buchanan (2002)
Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 35 4
A. Cotter, S. Vrouenraets, J. Brady, F. Wit, C. Fux, H. Furrer, K. Brinkman, C. Sabin, P. Reiss, P. Mallon (2013)
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.The Journal of clinical endocrinology and metabolism, 98 4
D. Bliuc, N. Nguyen, V. Milch, Tuan Nguyen, J. Eisman, J. Center (2009)
Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.JAMA, 301 5
M. Grijsen, S. Vrouenraets, F. Wit, I. Stolte, M. Prins, P. Lips, P. Reiss, J. Prins (2013)
Low bone mineral density, regardless of HIV status, in men who have sex with men.The Journal of infectious diseases, 207 3
L. Gazzola, G. Bellistrì, C. Tincati, V. Ierardi, A. Savoldi, A. Sole, L. Tagliabue, A. Monforte, G. Marchetti (2013)
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patientsJournal of Translational Medicine, 11
Sara Dolan, J. Kanter, S. Grinspoon (2006)
Longitudinal analysis of bone density in human immunodeficiency virus-infected women.The Journal of clinical endocrinology and metabolism, 91 8
M. Bolland, A. Grey, A. Horne, S. Briggs, Mark Thomas, R. Ellis-Pegler, Greg Gamble, I. Reid (2012)
Stable bone mineral density over 6 years in HIV‐infected men treated with highly active antiretroviral therapy (HAART)Clinical Endocrinology, 76
S. Manolagas (2000)
Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.Endocrine reviews, 21 2
T. Brown (2013)
HIV: An underrecognized secondary cause of osteoporosis?Journal of Bone and Mineral Research, 28
L. Rifas, M. Weitzmann (2009)
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner.Arthritis and rheumatism, 60 11
J. Fakruddin, J. Laurence (2004)
HIV-1 Vpr enhances production of receptor of activated NF-κB ligand (RANKL) via potentiation of glucocorticoid receptor activityArchives of Virology, 150
(2011)
Changes in bone biomarkers in ARV naïve HIVþ men randomized to NVP/ LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation
M. Yin, Chiyuan Zhang, D. McMahon, D. Ferris, D. Irani, I. Colon, S. Cremers, E. Shane (2012)
Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study.The Journal of clinical endocrinology and metabolism, 97 2
V. Triant, T. Brown, Hang Lee, S. Grinspoon (2008)
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.The Journal of clinical endocrinology and metabolism, 93 9
T. Brown, R. Qaqish (2006)
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS, 20
J. Hoy, B. Grund, Mollie Roediger, Kristine Ensrud, I. Brar, R. Colebunders, N. Castro, M. Johnson, Anjali Sharma, A. Carr (2013)
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyJournal of Bone and Mineral Research, 28
M. Yin, Dalian Lu, S. Cremers, P. Tien, Mardge Cohen, Q. Shi, E. Shane, E. Golub, K. Anastos (2010)
Short-Term Bone Loss in HIV-Infected Premenopausal WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 53
Allison Martin, Cecilia Moore, P. Mallon, J. Hoy, S. Emery, W. Belloso, P. Phanuphak, S. Ferret, D. Cooper, M. Boyd (2013)
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAIDS (London, England), 27
T. Brown, Yun Chen, J. Currier, H. Ribaudo, Jennifer Rothenberg, M. Dubé, R. Murphy, J. Stein, G. McComsey (2013)
Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy–Naive HIV-1–Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 63
B. Young, Christine Dao, K. Buchacz, R. Baker, J. Brooks (2011)
Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52 8
Seema Desai, A. Landay (2010)
Early Immune Senescence in HIV DiseaseCurrent HIV/AIDS Reports, 7
A. Hansen, J. Gerstoft, G. Kronborg, C. Larsen, C. Pedersen, G. Pedersen, N. Obel (2012)
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort studyAIDS, 26
(2013)
Recently published bone biomarker data from the SMART study demonstrate decreases in bone turnover markers and increases in BMD associated with treatment interruption
This was the first European study to determine an increased fracture risk in the HIVpositive population with the greatest risk in individuals with HIV/hepatitis C coinfection
A. Carr, John Miller, J. Eisman, D. Cooper (2001)
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapyAIDS, 15
P. D’Amelio, Anastasia Grimaldi, S. Bella, S. Brianza, M. Cristofaro, C. Tamone, G. Giribaldi, D. Ulliers, G. Pescarmona, G. Isaia (2008)
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.Bone, 43 1
W. El-Sadr, W. El-Sadr, J. Lundgren, J. Neaton, F. Gordin, D. Abrams, R. Arduino, A. Babiker, W. Burman, N. Clumeck, C. Cohen, D. Cohn, D. Cooper, J. Darbyshire, S. Emery, G. Fätkenheuer, B. Gazzard, B. Grund, J. Hoy, K. Klingman, M. Losso, N. Markowitz, J. Neuhaus, A. Phillips, C. Rappoport (2006)
CD4+ count-guided interruption of antiretroviral treatment.The New England journal of medicine, 355 22
G. McComsey, D. Kitch, E. Daar, C. Tierney, Nasreen Jahed, P. Tebas, Laurie Myers, K. Melbourne, B. Ha, P. Sax (2011)
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.The Journal of infectious diseases, 203 12
Madhulika Sharma, Shannon Callen, Da Zhang, P. Singhal, G. Heuvel, S. Buch (2010)
Activation of Notch signaling pathway in HIV-associated nephropathyAIDS, 24
A. Fausto, M. Bongiovanni, P. Cicconi, L. Menicagli, E. Ligabo, S. Melzi, T. Bini, F. Sardanelli, G. Cornalba, A. Monforte (2006)
Potential predictive factors of osteoporosis in HIV-positive subjects.Bone, 38 6
A. Isgrò, Wilma Leti, W. Santis, M. Marziali, A. Esposito, C. Fimiani, G. Luzi, M. Pinti, A. Cossarizza, F. Aiuti, I. Mezzaroma (2008)
Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46 12
H. Knobel, A. Guelar, G. Vallecillo, X. Nogués, A. Diez (2001)
Osteopenia in HIV-infected patients: is it the disease or is it the treatment?AIDS, 15 6
Youngnim Choi, Jeonghyeon Kim (2003)
B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesisExperimental & Molecular Medicine, 35
M. Yin, J. Dobkin, K. Brudney, C. Becker, J. Zadel, Monica Manandhar, V. Addesso, E. Shane (2005)
Bone mass and mineral metabolism in HIV+ postmenopausal womenOsteoporosis International, 16
J. Cauley, M. Danielson, R. Boudreau, K. Forrest, J. Zmuda, M. Pahor, F. Tylavsky, S. Cummings, Tamara Harris, A. Newman (2007)
Inflammatory Markers and Incident Fracture Risk in Older Men and Women: The Health Aging and Body Composition StudyJournal of Bone and Mineral Research, 22
J. Franco, A. Rubio, M. Martínez-Moya, M. Leal, E. Merchante, A. Sánchez-Quijano, E. Lissen (2002)
T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy.Blood, 99 10
M. Yong, J. Elliott, I. Woolley, J. Hoy (2011)
Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 57
T. Brown, G. McComsey, M. King, R. Qaqish, B. Bernstein, Barbara Silva (2009)
Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral RegimenJAIDS Journal of Acquired Immune Deficiency Syndromes, 51
Anjali Sharma, P. Flom, J. Weedon, R. Klein (2010)
Prospective study of bone mineral density changes in aging men with or at risk for HIV infectionAIDS, 24
REVIEW URRENT The effects of untreated and treated HIV infection PINION on bone disease a a,b Aoife G. Cotter and Patrick W.G. Mallon Purpose of review Low bone mineral density (BMD) is common in those with HIV, associated with higher bone turnover and a higher prevalence of fractures. This review explores low BMD in HIV, focusing on underlying mechanisms and relationships between low BMD and HIV infection, immune dysfunction, and antiretroviral therapy (ART). Recent findings Greater reductions in BMD accompanying reductions in HIV viremia at initiation of first-line or second-line ART suggest an important role for immune- or viral-mediated mechanisms in its pathogenesis. Summary As bone metabolism is part-regulated by T cells and B cells, we propose that earlier initiation of ART at higher CD4 T-cell counts may attenuate BMD loss by abrogating immune- and viral-mediated disturbances in bone metabolism that accompany ART initiation. Further pathogenesis-based research is required in this field, focusing on the complex interaction between virus, immune system, ART, and bone metabolism. Keywords B cells, bone, bone mineral density, fracture, HIV, immune dysfunction, T cells INTRODUCTION BONE DISEASE IN HIV-POSITIVE POPULATIONS: THE EXTENT AND With effective antiretroviral therapy (ART) leading CONSEQUENCE to increased lifespan in those
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Jan 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.